07:00 Tue 05 Dec 2017
OptiBiotix Health - Proposed directorate changes
("OptiBiotix" or the "Company")
Proposed directorate changes
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that subject to the completion of normal regulatory due diligence Neil Davidson CBE will be appointed as Non- Executive Chairman on
Neil brings to the Board over thirty years of operational and Board experience as Chairman and Chief Executive of
Neil has a wealth of commercial expertise in the food and retail sectors having started his career with
Neil's experience in the public markets includes non-executive positions with a number of
Neil has a personal interest in the development and commercialisation of technology to improve health. He was Chairman of Eminate, a spin out from the
On behalf of the Board, I would like to thank
For further information, please contact:
|
|||
|
Contact via Walbrook below |
||
|
|
||
|
Tel: 020 7213 0883 |
||
|
|
||
|
|
||
finnCap (Broker) |
Tel: 020 7220 0500 |
||
|
|
||
|
|
||
|
Tel: 020 7933 8780 or optibiotix@walbrookpr.com |
||
|
Mob: 07876 741 001 |
||
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
This information is provided by RNS
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE